Second, we built a culture that values impact over broad activity. As AI increasingly handles routine tasks that once ...

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...

Sanofi is a high-quality, undervalued pharma giant trading near 10x P/E. Click here to read more about SNY stock and why it ...

Cipla, a major pharmaceutical firm, is entering India's weight management market, focusing on obesity solutions. The company is also enhancing its CNS therapeutic offerings, having licensed Sanofi's ...

Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

In the latest twist in the ocean of Zantac-related litigation playing out across state courts, drugmakers have notched a key ...

Neutralizing Antibody Market is estimated to valued at USD 243.93 Bn in 2025 and expected reach USD 434.58 Bn by 2032, growing at CAGR of 8.6% from 2025 to 2032. BURLINGAME, CA, U ...

Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal ...

Sanofi is sponsoring the event for the second year in a row, which brings together 1,000 transplant recipients and live donors to compete.

Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to ...

The biotech is taking inspiration from cystic fibrosis treatment and applying a similar approach to developing "corrector" ...